In this virtual CE Concepts Grand Rounds, expert faculty will discuss strategies to better integrate diagnostic and prognostic biomarkers for DLBCL, utilize an evidence-based approach for personalizing treatment for patients with R/R DLBCL, and identify and mitigate the impact of AEs associated with novel therapies used in the treatment of patients with R/R DLBCL. See more information and collect credit here>>

In this CE Concepts Grand Rounds podcast, expert faculty will explore the latest clinical trial data on novel treatment options for patients with resistant/recurrent (R/R) CLL/SLL, utilization of an evidence-based approach for personalizing treatment for patients with R/R MCL, and prioritization of patient adherence and active engagement through development of multidisciplinary frameworks to oversee and address adverse events. The faculty will also provide insight through case-based discussions. Learn more: https://www.ceconcepts.com/activity/advancements-in-the-management-of-relapsed-refractory-b-cell-malignancies-integrating-recent-data-into-practice-to-improve-outcomes-2/

Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging, and highlight the need for targeted therapies based on molecular and genetic profiling to enhance treatment efficacy and reduce treatment-related adverse events (TRAEs). The role of CD30 expression further complicates patient care, because its variable expression among PTCL subtypes prevents establishing a uniform treatment approach. Though randomized clinical trial data is limited, these data can help refine treatment protocols and reduce the risk of relapse by identifying patients who may benefit from maintenance therapies or alternative treatment approaches.

In this CEC Oncology recorded Grand Rounds, expert faculty will evaluate the efficacy and safety of first-line PTCL treatments; explore the diagnostic, prognostic, and therapeutic applications of CD30 expression in PTCL subtypes; and discuss strategies to expand collaborative learning and communication that can enhance clinician understanding and proficiency in making informed therapeutic decisions as a treatment team.

Learn More: https://www.ceconcepts.com/activity/all-hands-on-deck-a-focus-on-current-and-emerging-treatment-options-in-the-frontline-setting-for-peripheral-t-cell-lymphoma-2/

The reduced incidence of cervical cancer over the past few decades was primarily due to robust screening guidelines and vaccinations. However, despite the proliferation of screening programs, the diagnosis of cervical cancer is associated with inefficiencies and inconsistencies and has not decreased cervical cancer incidence further over the past decade. Additionally, numerous health care disparities persist as unaddressed medical needs, particularly for individuals with marginalized sexualities and genders. An exciting array of new immunotherapy options are further emerging for patients with locally advanced, recurrent, or metastatic cervical cancer, with promising potential to heighten treatment effectiveness. It is imperative that clinicians and the multidisciplinary care team are appraised on these novel therapies and are conscious of health care disparities and unique patient needs.

In this CE Concepts recorded webcast, expert faculty will guide learners on the implementation of recommended, inclusive, and universal screening techniques and programs for cervical cancer. Faculty will also evaluate the latest efficacy and safety data in different settings for the treatment of cervical cancer as well as incorporate actionable strategies to address disparities and the unique health care of individuals with marginalized sexualities and genders related to cervical cancer screening.

Learn more: https://www.ceconcepts.com/activity/all-hands-on-deck-in-cervical-cancer-care-screening-treatment-and-equity-strategies-to-improve-patient-lives-2/

Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis) in MF. These clinicians and their interdisciplinary collaborative care team need a deeper understanding of JAKis in MF, guideline-recommended risk-stratification algorithms, molecular indicators of disease prognosis, clinical features of MF, symptom burden, the impact of adverse events on treatment adherence, and health disparities in MF.

In this CE Concepts recorded Grand Rounds, expert faculty will discuss assessing patients for MF therapy, integrating current and emerging data on JAKis in MF, developing individualized strategies to reduce treatment toxicity and enhance treatment adherence, and evaluating health disparities in MF. The faculty will also provide insight through case examples.

Learn More at: | https://www.ceconcepts.com/activity/all-hands-on-deck-utilizing-jak-inhibitors-in-myelofibrosis-care-evidence-timing-and-strategic-approaches/

The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This webcast will focus on emerging trial data for antibody-drug conjugates (ADCs); sequence optimization, combinatorial therapy utilization, and identification of when and in which patients to use ADCs; and anticipation, recognition, and management of treatment-related adverse events (TRAEs) in patients with metastatic urothelial cancer (mUC). Join our expert faculty for this 60-minute activity designed to help clinicians stay abreast of emerging trial data and evolving treatment guidelines, as well as effectively manage agent-specific AEs, to optimize care for their patients with mUC.

Learn more: https://www.ceconcepts.com/activity/tailoring-patient-care-using-novel-agents-in-metastatic-urothelial-carcinoma-strategies-for-the-interprofessional-team/

Patients with triple-negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients and results in treatment disparities. Antibody-drug conjugates (ADCs) are novel agents which may improve patient outcomes. However, clinicians cannot implement them into practice appropriately or may be hesitant to use them altogether.

In this Grand Rounds activity, a breast cancer expert will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).

Learn more: https://www.ceconcepts.com/activity/advancements-and-applications-of-antibody-drug-conjugates-in-her2-negative-breast-cancer/

Patients with triple-negative breast cancer (TNBC), and those with HR-positive/HER2-negative breast cancer after the development of endocrine resistance, have limited treatment options. Black women are diagnosed more often with TNBC and feel the lack of treatment options more acutely, leading to greater outcomes disparities. Antibody-drug conjugates (ADCs) are novel agents that may improve outcomes for patients. However, clinicians lack the ability to implement them into practice appropriately or may be hesitant to use them altogether. This 90-minute enduring activity is led by a panel of breast cancer experts who will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).

Learn more: https://www.ceconcepts.com/activity/transforming-metastatic-breast-cancer-management-harnessing-the-power-of-antibody-drug-conjugate-therapies-2/

Download the slides: https://www.ceconcepts.com/wp-content/uploads/2024/08/MM-140—ASCO—240606-1.pdf

Download the Transcript: https://www.ceconcepts.com/wp-content/uploads/2024/08/MMV-140-Transcript_FINAL.pdf